Literature DB >> 15688382

Comparison of the effects of the chemopreventive agent resveratrol and its synthetic analog trans 3,4,5,4'-tetramethoxystilbene (DMU-212) on adenoma development in the Apc(Min+) mouse and cyclooxygenase-2 in human-derived colon cancer cells.

Stewart Sale1, Richard G Tunstall, Ketan C Ruparelia, Gerry A Potter, William P Steward, Andreas J Gescher.   

Abstract

Naturally occurring molecules with putative cancer chemopreventive properties such as the phytoalexin resveratrol (3,5,4'-trihydroxystilbene) are lead molecules that guide the design of novel agents with improved pharmacologic properties. The synthetic resveratrol analog 3,4,5,4'-tetramethoxystilbene (DMU-212) has been shown to possess stronger antiproliferative properties in human colon cancer cells than resveratrol. We tested the hypothesis that DMU-212 is also a more potent inhibitor of adenoma development in the Apc(Min+) mouse, a model of human intestinal carcinogenesis. Apc(Min+) mice received either stilbene derivative with the diet (0.2%), and adenomas were counted after experiments were terminated. Resveratrol and DMU-212 decreased adenoma load by 27% and 24%, respectively, compared to untreated controls. Cyclooxygenase (COX) enzymes are important mechanistic targets of resveratrol, and we investigated whether DMU-212 interferes with the expression and activity of COX in human colon cells. Incubation of HCA-7 cancer cells for 24-96 hr with either stilbene derivative (1-50 microM) decreased prostaglandin E-2 (PGE-2) production, but only resveratrol decreased COX-2 protein expression. In mice, which received either stilbene derivative (0.2%) for 3 weeks with their diet, PGE-2 levels in the intestinal mucosa were reduced by between 45% and 62% compared to mice on control diet. While resveratrol inhibited enzyme activity in purified COX preparations, DMU-212 failed to do so. The PGE-2 decrease seen with DMU-212 in cells and in vivo is probably mediated via its metabolites. The results suggest that alteration of the resveratrol molecule to generate DMU-212 does not abrogate its ability to decrease adenoma number in Apc(Min+) mice or to interfere with PGE-2 generation in cells. Copyright 2005 Wiley-Liss, Inc

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15688382     DOI: 10.1002/ijc.20884

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  53 in total

1.  Subchronic oral toxicity and cardiovascular safety pharmacology studies of resveratrol, a naturally occurring polyphenol with cancer preventive activity.

Authors:  W D Johnson; R L Morrissey; A L Usborne; I Kapetanovic; J A Crowell; M Muzzio; D L McCormick
Journal:  Food Chem Toxicol       Date:  2011-09-10       Impact factor: 6.023

2.  Oncogenicity evaluation of resveratrol in p53(+/-) (p53 knockout) mice.

Authors:  T L Horn; M J Cwik; R L Morrissey; I Kapetanovic; J A Crowell; T D Booth; D L McCormick
Journal:  Food Chem Toxicol       Date:  2006-08-08       Impact factor: 6.023

3.  Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease.

Authors:  Saravanan S Karuppagounder; John T Pinto; Hui Xu; Huan-Lian Chen; M Flint Beal; Gary E Gibson
Journal:  Neurochem Int       Date:  2008-11-08       Impact factor: 3.921

4.  In vitro and in vivo studies on stilbene analogs as potential treatment agents for colon cancer.

Authors:  Shiby Paul; Cassia S Mizuno; Hong Jin Lee; Xi Zheng; Sarah Chajkowisk; John M Rimoldi; Allan Conney; Nanjoo Suh; Agnes M Rimando
Journal:  Eur J Med Chem       Date:  2010-05-15       Impact factor: 6.514

5.  2,3',4,4',5'-Pentamethoxy-trans-stilbene, a resveratrol derivative, inhibits colitis-associated colorectal carcinogenesis in mice.

Authors:  Haitao Li; William Ka Kei Wu; Zhi Jie Li; Kam Ming Chan; Clover Ching Man Wong; Cai Guo Ye; Le Yu; Joseph Jao Yiu Sung; Chi Hin Cho; Mingfu Wang
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

6.  The Anti-inflammatory Effect of Personalized Omega-3 Fatty Acid Dosing for Reducing Prostaglandin E2 in the Colonic Mucosa Is Attenuated in Obesity.

Authors:  Zora Djuric; D Kim Turgeon; Ananda Sen; Jianwei Ren; Kirk Herman; Devon Ramaswamy; Lili Zhao; Mack T Ruffin; Daniel P Normolle; William L Smith; Dean E Brenner
Journal:  Cancer Prev Res (Phila)       Date:  2017-11-13

7.  Increases in Colonic Bacterial Diversity after ω-3 Fatty Acid Supplementation Predict Decreased Colonic Prostaglandin E2 Concentrations in Healthy Adults.

Authors:  Zora Djuric; Christine M Bassis; Melissa A Plegue; Ananda Sen; D Kim Turgeon; Kirk Herman; Vincent B Young; Dean E Brenner; Mack T Ruffin
Journal:  J Nutr       Date:  2019-07-01       Impact factor: 4.798

8.  Role of microRNAs in resveratrol-mediated mitigation of colitis-associated tumorigenesis in Apc(Min/+) mice.

Authors:  Ibrahim Altamemi; E Angela Murphy; James F Catroppo; Elizabeth E Zumbrun; Jiajia Zhang; Jamie L McClellan; Udai P Singh; Prakash S Nagarkatti; Mitzi Nagarkatti
Journal:  J Pharmacol Exp Ther       Date:  2014-05-09       Impact factor: 4.030

9.  Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer.

Authors:  Kuzhuvelil B Harikumar; Ajaikumar B Kunnumakkara; Gautam Sethi; Parmeswaran Diagaradjane; Preetha Anand; Manoj K Pandey; Juri Gelovani; Sunil Krishnan; Sushovan Guha; Bharat B Aggarwal
Journal:  Int J Cancer       Date:  2010-07-15       Impact factor: 7.396

10.  Chemoprevention of benzo(a)pyrene-induced colon polyps in ApcMin mice by resveratrol.

Authors:  Ashley C Huderson; Jeremy N Myers; Mohammad S Niaz; Mary K Washington; Aramandla Ramesh
Journal:  J Nutr Biochem       Date:  2012-08-11       Impact factor: 6.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.